Mostra i principali dati dell'item

dc.contributor.authorPiscopo, Chiara
dc.date.accessioned2022-10-27T10:55:41Z
dc.date.available2022-10-27T10:55:41Z
dc.date.issued2021-05-07
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/6218
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-4306
dc.description2019 - 2020it_IT
dc.description.abstractN6-isopentenyladenosine (IPA) and its analogue N6-benzyladenosine (N6-BA) are modified nucleosides endowed with potent in vitro antitumor activity on different types of human cancers, including colorectal cancer (CRC) and glioblastoma multiforme (GBM). Although the molecules seem to exert their anti-proliferative effects partially through the inhibition of Farnesyl Diphosphate Synthase (FDPS), their precise mechanisms of action remain to be uncovered. The main aim of my PhD project was to investigate the effects of the isoprenoid derivative N6-BA, by comparing them to those of the lead compound IPA, on the modulation of cancer-related pathways. I found that both IPA and N6-BA affect CRC and GBM cell lines proliferation by modulating the expression of the F-box WD repeat domain-containing 7 (FBXW7), widely considered a tumor suppressor since its crucial role in the turnover of many proteins (i.e. c-Myc, SREBPs and Mcl1) contributing to malignant progression. In CRC, FBXW7/SREBP/FDPS axis was identified as a target of the compounds. IPA was found to induce the ubiquitination of c-Myc, inhibiting its transcriptional activity through the increase of FBXW7/c-Myc binding and N6-BA acts almost in a similar way. Moreover, IPA involvement in chemoresistance was also investigated. IPA synergized with 5-Fluorouracil in FBXW7- and TP53-wild type CRC cells and sensitized GBM cells to the toxic effect of Temozolomide. Overall, results here showed provide novel insights into the molecular mechanism of the modified adenosines and suggested the existence of an epigenetic regulation underlying their pleiotropic effects in cancer. Restoring of FBXW7 tumor-suppressor represents a valid therapeutic tool, enabling modified adenosines as optimizable compound for patient-personalized therapies in both CRC and GBM.[edited by Author]it_IT
dc.language.isoenit_IT
dc.publisherUniversita degli studi di Salernoit_IT
dc.subjectN6-benziladenosinait_IT
dc.subjectCancer progressionit_IT
dc.subjectColorectal Cancerit_IT
dc.subjectGlioblastomait_IT
dc.titleEffects of the isoprenoid derivative N6-benzyladenosine in cancer progressionit_IT
dc.typeDoctoral Thesisit_IT
dc.subject.miurMED/04 PATOLOGIA GENERALEit_IT
dc.contributor.coordinatoreSbardella, Gianlucait_IT
dc.description.cicloXXXIII cicloit_IT
dc.contributor.tutorGazzerra, Patriziait_IT
dc.identifier.DipartimentoFarmaciait_IT
 Find Full text

Files in questo item

Thumbnail
Thumbnail
Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item